Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
Withdrawn
- Conditions
- MeningiomaGlioma
- Interventions
- Procedure: Blood test
- Registration Number
- NCT00985036
- Lead Sponsor
- Marquette General Health System
- Brief Summary
Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:
1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
2. Is the VEGF level an indicator of the response to treatment?
3. Does the VEGF level correlate with tumor histology and behavior?
4. Is there a relationship between VEGF level and outcome?
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- any patient presenting with glioma or meningioma
Exclusion Criteria
- a different type of brain tumor
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description meningioma Blood test patients who are diagnosed with and are being treated for meningioma Glioma Blood test patients who are diagnosed with and are being treated for glioma
- Primary Outcome Measures
Name Time Method Determine if VEGF levels correlate with tumor progression or recurrence every one to three months
- Secondary Outcome Measures
Name Time Method Determine if the VEGF level correlates with tumor histology and behavior. Every one to three months Determine if the VEGF level is an indicator of the response to treatment. Every one to three months Determine if there is a relationship between VEGF level and outcome. Every one to three months
Trial Locations
- Locations (1)
Marquette General Hospital
🇺🇸Marquette, Michigan, United States